Amphastar Pharmaceuticals (29A) Stock Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

29A Analyst Ratings

Hold

0 Buy

5 Hold

1 Sell

Based on 6 analysts giving stock ratings to

Amphastar

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

29A Stock 12 Month Forecast

Average Price Target

€19.49

▲(5.68% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Amphastar Pharmaceuticals in the last 3 months. The average price target is €19.49 with a high forecast of €26.37 and a low forecast of €17.58. The average price target represents a 5.68% change from the last price of €18.44.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"€14","27":"€27","17.25":"€17.25","20.5":"€20.5","23.75":"€23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26.3739045,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€26.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.48738499166667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€19.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.582603,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€17.58</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,17.25,20.5,23.75,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.935,19.507223423076923,20.079446846153846,20.651670269230767,21.22389369230769,21.796117115384614,22.36834053846154,22.94056396153846,23.512787384615383,24.085010807692306,24.65723423076923,25.229457653846154,25.801681076923074,{"y":26.3739045,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.935,18.977491153205126,19.019982306410256,19.062473459615383,19.104964612820513,19.14745576602564,19.18994691923077,19.232438072435897,19.274929225641028,19.317420378846155,19.359911532051285,19.402402685256412,19.444893838461542,{"y":19.48738499166667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.935,18.83096946153846,18.726938923076922,18.622908384615382,18.518877846153845,18.414847307692305,18.31081676923077,18.20678623076923,18.102755692307692,17.998725153846152,17.894694615384616,17.790664076923075,17.686633538461535,{"y":17.582603,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.64,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.24,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.53,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.465,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.93,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.695,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":17.135,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":17.295,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.935,"date":1788220800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€26.37

Average Price Target€19.49

Lowest Price Target€17.58

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Benjamin Burnett

Wells Fargo

€17.58

Hold

-4.65%

Downside

Reiterated

09/02/26

Wells Fargo Sticks to Their Hold Rating for Amphastar Pharmaceuticals (AMPH)

Glen Santangelo

Barclays

€17.58→€20.22

Hold

9.65%

Upside

Reiterated

08/18/26

Amphastar price target raised to $23 from $20 at BarclaysAmphastar price target raised to $23 from $20 at Barclays

Jason Gerberry

Bank of America Securities

€17.58

Sell

-4.65%

Downside

Reiterated

08/07/26

Bank of America Securities Keeps Their Sell Rating on Amphastar Pharmaceuticals (AMPH)

David Amsellem

Piper Sandler

€18.46→€17.58

Hold

-4.65%

Downside

Reiterated

08/07/26

Amphastar Pharmaceuticals (AMPH) Gets a Hold from Piper Sandler

Serge Belanger

Needham

€17.58

Hold

-4.65%

Downside

Reiterated

08/07/26

Analysts Conflicted on These Healthcare Names: Amphastar Pharmaceuticals (NASDAQ: AMPH), Tenax Therapeutics (NASDAQ: TENX) and Definium Therapeutics (NASDAQ: DFTX)

Unknown Analyst

J.P. Morgan

Not Ranked

J.P. Morgan

€26.37

Hold

43.03%

Upside

Reiterated

07/23/26

Amphastar Pharmaceuticals (AMPH) Gets a Hold from J.P. Morgan

Dennis Ding

Jefferies

€26.37→€19.34

Hold

4.89%

Upside

Downgraded

04/21/26

Amphastar downgraded to Hold from Buy at JefferiesAmphastar downgraded to Hold from Buy at Jefferies

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Benjamin Burnett

Wells Fargo

€17.58

Hold

-4.65%

Downside

Reiterated

09/02/26

Wells Fargo Sticks to Their Hold Rating for Amphastar Pharmaceuticals (AMPH)

Glen Santangelo

Barclays

€17.58→€20.22

Hold

9.65%

Upside

Reiterated

08/18/26

Amphastar price target raised to $23 from $20 at BarclaysAmphastar price target raised to $23 from $20 at Barclays

Jason Gerberry

Bank of America Securities

€17.58

Sell

-4.65%

Downside

Reiterated

08/07/26

Bank of America Securities Keeps Their Sell Rating on Amphastar Pharmaceuticals (AMPH)

David Amsellem

Piper Sandler

€18.46→€17.58

Hold

-4.65%

Downside

Reiterated

08/07/26

Amphastar Pharmaceuticals (AMPH) Gets a Hold from Piper Sandler

Serge Belanger

Needham

€17.58

Hold

-4.65%

Downside

Reiterated

08/07/26

Analysts Conflicted on These Healthcare Names: Amphastar Pharmaceuticals (NASDAQ: AMPH), Tenax Therapeutics (NASDAQ: TENX) and Definium Therapeutics (NASDAQ: DFTX)

Unknown Analyst

J.P. Morgan

Not Ranked

J.P. Morgan

€26.37

Hold

43.03%

Upside

Reiterated

07/23/26

Amphastar Pharmaceuticals (AMPH) Gets a Hold from J.P. Morgan

Dennis Ding

Jefferies

€26.37→€19.34

Hold

4.89%

Upside

Downgraded

04/21/26

Amphastar downgraded to Hold from Buy at JefferiesAmphastar downgraded to Hold from Buy at Jefferies

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

LFMDLifeMD

ORKAOruka Therapeutics

ACHVAchieve Life Sciences

PLSEPulse Biosciences

PMNProMIS Neurosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amphastar Pharmaceuticals

3 Months

Google Drug Manufacturers - Specialty and GenericTipRanks - Google

Success Rate

0/2 ratings generated profit

Average Return

-6.90%

Copying Google Drug Manufacturers - Specialty and Generic's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -6.90% per trade.

1 Year

Google Drug Manufacturers - Specialty and GenericTipRanks - Google

Success Rate

0/2 ratings generated profit

Average Return

-6.90%

Copying Google Drug Manufacturers - Specialty and Generic's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -6.90% per trade.

2 Years

Google Drug Manufacturers - Specialty and GenericTipRanks - Google

Success Rate

0/2 ratings generated profit

Average Return

-6.90%

Copying Google Drug Manufacturers - Specialty and Generic's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -6.90% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

29A Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 29A has received 0 Buy Ratings, 7 Hold Ratings, and 1 Sell Ratings. 29A average Analyst price target in the past 3 months is 19.49.

Each month's total comprises the sum of three months' worth of ratings.

29A Financial Forecast

29A Earnings Forecast

Next quarter’s earnings estimate for 29A is €0.75 with a range of €0.60 to €0.91. The previous quarter’s EPS was €0.79. 29A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 29A has Performed in-line its overall industry.

29A Sales Forecast

Next quarter’s sales forecast for 29A is €170.88M with a range of €159.00M to €178.78M. The previous quarter’s sales results were €158.83M. 29A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 29A has Performed in-line its overall industry.

29A Stock Forecast FAQ

What is DE:29A’s average 12-month price target, according to analysts?

Based on analyst ratings, Amphastar Pharmaceuticals’s 12-month average price target is 19.49.

What is DE:29A’s upside potential, based on the analysts’ average price target?

Amphastar Pharmaceuticals has 5.68% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Amphastar Pharmaceuticals a Buy, Sell or Hold?

Amphastar Pharmaceuticals has a consensus rating of Hold, which is based on 0 buy ratings, 5 hold ratings and 1 sell ratings.

What is Amphastar Pharmaceuticals’s share price target?

The average share price target for Amphastar Pharmaceuticals is 19.49. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €26.37 ,and the lowest forecast is €17.58. The average share price target represents 5.68% Increase from the current price of €18.44.

What do analysts say about Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals’s analyst rating consensus is a Hold. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Amphastar Pharmaceuticals?

To buy shares of DE:29A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Amphastar Pharmaceuticals (29A) Stock Forecast & Price Target

29A Analyst Ratings

29A Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amphastar Pharmaceuticals

29A Analyst Recommendation Trends

29A Financial Forecast

29A Earnings Forecast

29A Sales Forecast

29A Stock Forecast FAQ

Detailed List of Analyst Forecasts